Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 6/20 | 0.49 |
| ▸ | ABL1 | P00519 | 4/20 | 0.49 |
| ▸ | PRKCA | P17252 | 3/20 | 0.49 |
| ▸ | SRC | P12931 | 1/20 | 0.49 |
| ▸ | ABL2 | P42684 | 1/20 | 0.46 |
| ▸ | CDC7 | O00311 | 2/20 | 0.45 |
| ▸ | GSK3B | P49841 | 2/20 | 0.45 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.45 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.45 |
| ▸ | PIM1 | P11309 | 1/20 | 0.45 |
| ▸ | PRKACA | P17612 | 1/20 | 0.45 |
| ▸ | CDK2 | P24941 | 1/20 | 0.45 |
| ▸ | HIPK2 | Q9H2X6 | 1/20 | 0.45 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.45 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.45 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 3/20 | 0.45 |
| ▸ | MAPT | P10636 | 2/20 | 0.45 |
| ▸ | HPGD | P15428 | 2/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6235344 | 0.94 | EGFR (0.55) | EGFRABL1PRKCASRCABL2 | |
| SCHEMBL6682618 | 0.91 | EGFR (0.49) | EGFRABL1PRKCASRCCDC7 | |
| SCHEMBL6684888 | 0.88 | EGFR (0.52) | EGFRABL1PRKCASRCABL2 | |
| SCHEMBL19507769 | 0.88 | EGFR (0.52) | EGFRABL1PRKCASRCCDK1 | |
| SCHEMBL6686751 | 0.88 | EGFR (0.52) | EGFRABL1PRKCASRCABL2 | |
| SCHEMBL6238000 | 0.87 | ABCG2 (0.51) | EGFRABL1PRKCASRCABL2 | |
| SCHEMBL6689654 | 0.87 | FGFR1 (0.57) | EGFRABL1PRKCALMNAMAPT | |
| SCHEMBL13861667 | 0.85 | TTBK1 (0.52) | EGFRABL1PRKCASRCABL2 | |
| SCHEMBL6684639 | 0.84 | LMNA (0.57) | EGFRABL1PRKCASRCABL2 | |
| SCHEMBL19507717 | 0.83 | CDC7 (0.47) | EGFRABL1SRCCDC7GSK3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190119284-A1 | ErbB Inhibitors and Uses Thereof | THE SCRIPPS RESEARCH INSTITUTE | 2019-04-25 | — | — | US | disclosed |
| WO-2017184775-A1 | ERBB INHIBITORS AND USES THEREOF | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2017-10-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190119284-A1 | ErbB Inhibitors and Uses Thereof | ERBB3, ERBB2, EGFR | EGFR 3/4885ABL1 6/4885PRKCA 761/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.